GeneCentric -Lung Cancer Profilers (LSP)
GeneCentric has developed two gene expression profilers (LSP 210 and LSP 220) that define molecular subtypes of the two most common forms of non-small cell lung cancer (NSCLC), squamous cell carcinoma, and adenocarcinoma.
Published studies have demonstrated that the subtypes, while indistinguishable by standard morphology, have different genetic, molecular and clinical attributes yielding immune profiles that have potential to drive drug response. The most recent study, published in the Journal of Thoracic Oncology (June 2017), demonstrated distinct differences among the subtypes in the immune landscape. GeneCentric is applying its LSs in a collaboration with Bristol-Myers Squibb to determine their potential to identify drug response populations to the immuno-therapy Opdivo® (nivolumab). GeneCentric demonstrated initial validation of its subtyping approach with a genomic signature panel (LSP 110) that distinguishes NSCLC tumors from neuroendocrine tumors. Through an agreement with LabCorp, LSP 110 panel is commercially available as HistoPlus™.